5 Biotech Stocks to Buy According to Matthew Strobeck’s Birchview Capital

Page 1 of 5

In this article, we discuss 5 biotech stocks to buy according to Matthew Strobeck’s Birchview Capital. If you want to read our detailed analysis of Strobeck’s history, investment philosophy, and hedge fund performance, go directly to 10 Biotech Stocks to Buy According to Matthew Strobeck’s Birchview Capital.

5. Foghorn Therapeutics Inc. (NASDAQ:FHTX)

Birchview Capital Stake Value: $4,376,000
Percentage of Birchview Capital’s 13F Portfolio: 2.97%
Number of Hedge Fund Holders: 7

Foghorn Therapeutics Inc. (NASDAQ:FHTX) is a biotechnology business in the early stages of developing a new class of drugs that target the chromatin regulatory system. H.C. Wainwright analyst Andrew Fein commenced coverage of Foghorn Therapeutics Inc. (NASDAQ:FHTX) with a Buy rating and a price target of $25 on November 22.

Euclidean Capital owns 1.26 million shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX), worth over $17.57 million, and is the leading stakeholder of the company out of the 867 hedge funds tracked by Insider Monkey in the third quarter of 2021. Next on the list of the significant stakeholders of Foghorn Therapeutics Inc. (NASDAQ:FHTX) is Matthew Strobeck’s Birchview Capital, which owns 314,143 shares of the company, worth over $4.38 million.

At the end of the third quarter of 2021, 7 hedge funds in the database of Insider Monkey held stakes worth $31.22 million in Foghorn Therapeutics Inc. (NASDAQ:FHTX), up from 5 funds in the preceding quarter, holding stakes in Foghorn Therapeutics Inc. (NASDAQ:FHTX) totalling $22.10 million.

Page 1 of 5